Cargando…

Treatment patterns and health care resource use in patients receiving multiple lines of therapy for metastatic squamous cell carcinoma of the head and neck in the United Kingdom

This study evaluated the patterns of care and health care resource use (HCRU) in patients with metastatic squamous cell carcinoma of the head and neck (SCCHN) who received ≥3 lines of systemic therapy in the United Kingdom (UK). Oncologists (n = 40) abstracted medical records for patients with metas...

Descripción completa

Detalles Bibliográficos
Autores principales:	La, Elizabeth M., Smyth, Emily Nash, Talbird, Sandra E., Li, Li, Kaye, James A., Lin, Aimee Bence, Bowman, Lee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175088/ https://www.ncbi.nlm.nih.gov/pubmed/29927010 http://dx.doi.org/10.1111/ecc.12862

Ejemplares similares

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck
por: Mesía, R., et al.
Publicado: (2010)

Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borcoman, Edith, et al.
Publicado: (2021)

Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma
por: Black, Christopher M., et al.
Publicado: (2023)

Corrigendum: Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma
por: Black, Christopher M., et al.
Publicado: (2023)

Osteopontin Levels in Patients with Squamous Metastatic Head and Neck Cancer
por: Maleš, Josip, et al.
Publicado: (2021)

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Hsieh, Ronan W., et al.
Publicado: (2021)

Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab
por: Tanoue, Kenro, et al.
Publicado: (2021)

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial(†)
por: Clement, P. M., et al.
Publicado: (2016)

Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina
por: Wurcel, Victoria, et al.
Publicado: (2021)

Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands
por: van der Linden, Naomi, et al.
Publicado: (2015)

Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
por: Chen, Wen-Chun, et al.
Publicado: (2017)

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borel, Christian, et al.
Publicado: (2020)

Socioeconomic factors and survival in patients with non‐metastatic head and neck squamous cell carcinoma
por: Xu, Cheng, et al.
Publicado: (2017)

The Prognostic Value of TP53 Alteration in Patients with Head and Neck Squamous Cell Carcinoma Receiving Immunotherapy
por: Jiang, Chao, et al.
Publicado: (2022)

The association between body mass index and efficacy of pembrolizumab as second‐line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma
por: Zhang, Xinyi, et al.
Publicado: (2022)

Effect of ethanol extracts of Antrodia cinnamomea on head and neck squamous cell carcinoma cell line
por: Liu, Li, et al.
Publicado: (2020)

p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy
por: Ganly, I, et al.
Publicado: (2000)

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck
por: Pivot, X, et al.
Publicado: (2001)

Mechanisms of cyst formation in metastatic lymph nodes of head and neck squamous cell carcinoma
por: Mokhtari, Sepideh
Publicado: (2012)

Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer
por: Lorch, Jochen H
Publicado: (2009)

Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck
por: Sukari, Ammar, et al.
Publicado: (2015)

Curative treatment can be an option for patients with metastatic squamous cell cancer of the head and neck
por: Guenne, Clémence, et al.
Publicado: (2014)

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Argiris, Athanassios, et al.
Publicado: (2017)

Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma
por: Arron, Sarah T., et al.
Publicado: (2022)

Efficacy and Safety of Iodine-125 Brachytherapy in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wu, Chunrong, et al.
Publicado: (2020)

Management of neck metastases in head and neck cancer: United Kingdom National Multidisciplinary Guidelines
por: Paleri, V, et al.
Publicado: (2016)

HBD3 Induces PD-L1 Expression on Head and Neck Squamous Cell Carcinoma Cell Lines
por: Gomez Hernandez, Maria Paula, et al.
Publicado: (2019)

Biomarkers in wound drainage fluids of head and neck squamous cell carcinoma patients receiving neck dissection: A pilot study
por: Gualtieri, Tommaso, et al.
Publicado: (2020)

Hypoxia in Head and Neck Squamous Cell Carcinoma
por: Li, John Zenghong, et al.
Publicado: (2012)

Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group
por: Klinghammer, Konrad, et al.
Publicado: (2022)

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
por: Cavalieri, Stefano, et al.
Publicado: (2021)

Ten human carcinoma cell lines derived from squamous carcinomas of the head and neck.
por: Easty, D. M., et al.
Publicado: (1981)

Next-generation sequencing identifies CDKN2A alterations as prognostic biomarkers in recurrent or metastatic head and neck squamous cell carcinoma predominantly receiving immune checkpoint inhibitors
por: Xue, Liqiong, et al.
Publicado: (2023)

Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule
por: Pêtre, Adeline, et al.
Publicado: (2018)

The Optimal Second-Line Systemic Treatment Model for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Bayesian Network Meta-Analysis
por: Zhan, Ze-Jiang, et al.
Publicado: (2021)

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck
por: Rubió-Casadevall, Jordi, et al.
Publicado: (2023)

A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck
por: Couteau, C, et al.
Publicado: (1999)

MicroRNA-141 suppresses growth and metastatic potential of head and neck squamous cell carcinoma
por: Zhao, Zhiguo, et al.
Publicado: (2019)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Taberna, Miren, et al.
Publicado: (2019)

Circulating tumor cell analysis in locally advanced and metastatic squamous cell carcinoma of the head and neck
por: Harris, Ethan J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9ptq84r4c85bnis6rtcipbu16o